Piper Sandler Reiterates Overweight on Moderna, Raises Price Target to $305
Benzinga Newsdesk 15 hours ago
Analyst RatingsNewsReiterationPrice TargetHot
Piper Sandler analyst Edward Tenthoff reiterates Moderna (NASDAQ:MRNA) with a Overweight and raises the price target from $230 to $305.
Piper Sandler analyst Edward Tenthoff reiterates Moderna (NASDAQ:MRNA) with a Overweight and raises the price target from $230 to $305.